No side effect is NEWs!!! In fact for trials of this kind (phase I), no news IS news.
Phase I trial is mainly to determine safety and look for adverse side effects. It is clear that the cohort should therefore be small group. To that end this trial is successful and on track. This is in face THE NEWS we were hoping for! In absence of adverse side effect, a partial response seen here with low fosage is a bonus and even an eary encouraging indication for a phase II trial. Here, we are talking about advanced metastetic disease (solid tumour) with no other therapy option!!!! Those who expect miracle from first part of a phase I trial either don't know anything about any of this OR they are day traders who should look into other sectors. Biotechnology and oncology is NOT your playing field if you are a day trader.
In saying that, if we get some results with this next 6 patients, with elevated dosage, by end H1/2020 and entering phase II then, is a REALLY good progress.
And remember, this is not our only trial.
- Forums
- ASX - By Stock
- IMM
- Ann: INSIGHT-004 clinical trial update
Ann: INSIGHT-004 clinical trial update, page-18
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $443.6M |
Open | High | Low | Value | Volume |
31.0¢ | 31.8¢ | 30.5¢ | $1.050M | 3.399M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 334744 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 5285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 334744 | 0.305 |
25 | 429113 | 0.300 |
9 | 120834 | 0.295 |
11 | 509636 | 0.290 |
9 | 1056625 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 5285 | 1 |
0.315 | 7174 | 2 |
0.320 | 115546 | 6 |
0.325 | 239718 | 4 |
0.330 | 26299 | 3 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online